ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA(R) in BCG-Unresponsive Papillary Bladder Cancer

Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA ...
Seeking Alpha

ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA ® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Seeking Alpha

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA ® (nogapendekin alfa inbakicept-pmln) in ...
Renal & Urology News

Cretostimogene Durability Confirmed in CIS-Containing BCG-Unresponsive NMIBC

Cretostimogene for CIS-containing BCG unresponsive nonmuscle-invasive bladder cancer showed “best in class durability and tolerability,” according to investigators. Cretostimogene grenadenorepvec ...
Nasdaq

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Oral presentation provides update from QUILT-3.032 on durable complete responses to ANKTIVA® plus BCG in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) with or ...